1. Nussinov R, Tsai CJ, Jang H. A new view of pathway-driven drug resistance in tumor proliferation. Trends Pharmacol Sci 2017;38:427-37.

2. Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in cancer metabolism: new concepts in an old field. Antioxid Redox Signal 2016;26:462-85.

3. Gupta PB, Pastushenko I, Skibinski A, Blanpain C, Kuperwasser C. Phenotypic plasticity: driver of cancer initiation, progression, and therapy resistance. Cell Stem Cell 2019;24:65-78.

4. Vargas-Roig LM, Gago FE, Tello O, Aznar JC, Ciocca DR. Heat shock protein expression and drug resistance in breast cancer patients treated with induction chemotherapy. Int J Cancer 1998;79:468-75.

5. Stope MB, Koensgen D, Burchardt M, Concin N, Zygmunt M, et al. Jump in the fire - heat shock proteins and their impact on ovarian cancer therapy. Crit Rev Oncol Hematol 2016;97:152-6.

6. Yallowitz A, Ghaleb A, Garcia L, Alexandrova EM, Marchenko N. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells article. Cell Death Dis 2018;9:621.

7. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 2006;580:2903-9.

8. Jang B, Kwon H, Katila P, Lee SJ, Lee H. Dual delivery of biological therapeutics for multimodal and synergistic cancer therapies. Adv Drug Deliv Rev 2016;98:113-33.

9. Liu JP, Wang TT, Wang DG, Dong AJ, Li YP, et al. Smart nanoparticles improve therapy for drug-resistant tumors by overcoming pathophysiological barriers. Acta Pharmacol Sin 2017;38:1-8.

10. Zhang RX, Wong HL, Xue HY, Eoh JY, Wu XY. Nanomedicine of synergistic drug combinations for cancer therapy - Strategies and perspectives. J Control Release 2016;240:489-503.

11. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, et al. International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy. J Natl Cancer Inst 2009;101:1174-81.

12. Zhang B, Hu Y, Pang Z. Modulating the tumor microenvironment to enhance tumor nanomedicine delivery. Front Pharmacol 2017;8:952.

13. Tashima T. Effective cancer therapy based on selective drug delivery into cells across their membrane using receptor-mediated endocytosis. Bioorganic Med Chem Lett 2018;28:3015-24.

14. Cui J, Yue JB. Current status and advances in arginine-glycine-aspartic acid peptide-based molecular imaging to evaluate the effects of anti-angiogenic therapies. Precis Radiat Oncol 2019;3:29-34.

15. Carpenter RO, Evbuomwan MO, Pittaluga S, Rose JJ, Raffeld M, et al. B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma. Clin Cancer Res 2013;19:2048-60.

16. Acres B, Limacher JM. MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 2005;4:493-502.

17. Mattheolabakis G, Milane L, Singh A, Amiji MM. Hyaluronic acid targeting of CD44 for cancer therapy: from receptor biology to nanomedicine. J Drug Target 2015;23:605-18.

18. Saneja A, Arora D, Kumar R, Dubey RD, Panda AK, et al. CD44 targeted PLGA nanomedicines for cancer chemotherapy. Eur J Pharm Sci 2018;121:47-58.

19. Necas J, Bartosikova L, Brauner P, Kolar J. Hyaluronic acid (hyaluronan): a review. Vet Med (Praha) 2008;53:397-411.

20. Sun Y, Li X, Zhang L, Liu X, Jiang B, et al. Cell permeable NBD peptide-modified liposomes by hyaluronic acid coating for the synergistic targeted therapy of metastatic inflammatory breast cancer. Mol Pharm 2019;16:1140-55.

21. Dufay Wojcicki A, Hillaireau H, Nascimento TL, Arpicco S, Taverna M, et al. Hyaluronic acid-bearing lipoplexes: physico-chemical characterization and in vitro targeting of the CD44 receptor. J Control Release 2012;162:545-52.

22. Nascimento TL, Hillaireau H, Vergnaud J, Fattal E. Lipid-based nanosystems for CD44 targeting in cancer treatment: recent significant advances, ongoing challenges and unmet needs. Nanomedicine 2016;11:1865-87.

23. Dosio F, Arpicco S, Stella B, Fattal E. Hyaluronic acid for anticancer drug and nucleic acid delivery. Adv Drug Deliv Rev 2016;97:204-36.

24. Nascimento TL, Hillaireau H, Noiray M, Bourgaux C, Arpicco S, et al. Supramolecular organization and siRNA binding of hyaluronic acid-coated lipoplexes for targeted delivery to the CD44 receptor. Langmuir 2015;31:11186-94.

25. Lee SY, Cho HJ. Mitochondria targeting and destabilizing hyaluronic acid derivative-based nanoparticles for the delivery of lapatinib to triple-negative breast cancer. Biomacromolecules 2019;20:835-45.

26. Tevaarwerk AJ, Kolesar JM. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer. Clin Ther 2009;31:2332-48.

27. Zhang M, Ma Y, Wang Z, Han Z, Gao W, et al. A CD44-targeting programmable drug delivery system for enhancing and sensitizing chemotherapy to drug-resistant cancer. ACS Appl Mater Interfaces 2019;11:5851-61.

28. Lu L, Ding Y, Zhang Y, Ho RJY, Zhao Y, et al. Antibody-modified liposomes for tumor-targeting delivery of timosaponin AIII. Int J Nanomedicine 2018;13:1927-44.

29. Kennedy PJ, Sousa F, Ferreira D, Pereira C, Nestor M, et al. Fab-conjugated PLGA nanoparticles effectively target cancer cells expressing human CD44v6. Acta Biomater 2018;81:208-18.

30. Alshaer W, Hillaireau H, Fattal E. Aptamer-guided nanomedicines for anticancer drug delivery. Adv Drug Deliv Rev 2018;134:122-37.

31. Ismail SI, Alshaer W. Therapeutic aptamers in discovery, preclinical and clinical stages. Adv Drug Deliv Rev 2018;134:51-64.

32. Alshaer W, Hillaireau H, Vergnaud J, Ismail S, Fattal E. Functionalizing Liposomes with anti-CD44 aptamer for selective targeting of cancer cells. Bioconjug Chem 2015;26:1307-13.

33. Alshaer W, Hillaireau H, Vergnaud J, Mura S, Deloménie C, et al. Aptamer-guided siRNA-loaded nanomedicines for systemic gene silencing in CD-44 expressing murine triple-negative breast cancer model. J Control Release 2018;271:98-106.

34. Lou S, Zhao Z, Dezort M, Lohneis T, Zhang C. Multifunctional nanosystem for targeted and controlled delivery of multiple chemotherapeutic agents for the treatment of drug-resistant breast cancer. ACS Omega 2018;3:9210-9.

35. Zhou L, Wang H, Li Y. Stimuli-responsive nanomedicines for overcoming cancer multidrug resistance. Theranostics 2018;8:1059-74.

36. Qin SY, Cheng YJ, Lei Q, Zhang AQ, Zhang XZ. Combinational strategy for high-performance cancer chemotherapy. Biomaterials 2018;171:178-97.

37. Chen M, Liang X, Gao C, Zhao R, Zhang N, et al. Ultrasound triggered conversion of porphyrin/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal cancer. ACS Nano 2018;12:7312-26.

38. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol 2015;33:941-51.

39. Mu X, Li J, Yan S, Zhang H, Zhang W, et al. SiRNA Delivery with stem cell membrane-coated magnetic nanoparticles for imaging-guided photothermal therapy and gene therapy. ACS Biomater Sci Eng 2018;4:3895-905.

40. Cheng G, Li W, Ha L, Han X, Hao S, et al. Self-Assembly of Extracellular Vesicle-like Metal–Organic Framework Nanoparticles for Protection and Intracellular Delivery of Biofunctional Proteins. J Am Chem Soc 2018;140:7282-91.

41. He H, Guo C, Wang J, Korzun WJ, Wang XY, et al. Leutusome: A Biomimetic Nanoplatform Integrating Plasma Membrane Components of Leukocytes and Tumor Cells for Remarkably Enhanced Solid Tumor Homing. Nano Lett 2018;18:6164-74.

42. Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, et al. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano 2017;11:12-8.

43. Mülhopt S, Diabaté S, Dilger M, Adelhelm C, Anderlohr C, et al. Characterization of nanoparticle batch-to-batch variability. Nanomaterials 2018;8:311.

44. Wilhelm S, Tavares AJ, Dai Q, Ohta S, Audet J, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater 2016;1:16014.

45. Zhang YN, Poon W, Tavares AJ, McGilvray ID, Chan WCW. Nanoparticle-liver interactions: cellular uptake and hepatobiliary elimination. J Control Release 2016;240:332-48.

46. Rasmussen K, Rauscher H, Mech A, Riego Sintes J, Gilliland D, et al. Physico-chemical properties of manufactured nanomaterials - characterisation and relevant methods. An outlook based on the OECD Testing Programme. Regul Toxicol Pharmacol 2018;92:8-28.

47. Hoter A, El-Sabban ME, Naim HY. The HSP90 family: structure, regulation, function, and implications in health and disease. Int J Mol Sci 2018;19:2560.

48. Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol 2017;18:345-60.

49. Prodromou C. Mechanisms of Hsp90 regulation. Biochem J 2016;473:2439-52.

50. Canonici A, Qadir Z, Conlon NT, Collins DM, O’Brien NA, et al. The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells. Invest New Drugs 2018;36:581-9.

51. Zhang G, Zhang H, Liu Y, He Y, Wang W, et al. CD44 clustering is involved in monocyte differentiation. Acta Biochim Biophys Sin (Shanghai) 2014;46:540-7.

52. Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, et al. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: overview and current state of the art. Biomed Pharmacother 2018;102:608-17.

53. Wang Y, McAlpine SR. N-terminal and C-terminal modulation of Hsp90 produce dissimilar phenotypes. Chem Commun (Camb) 2015;51:1410-3.

54. Wang X, Chen M, Zhou J, Zhang X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review). Int J Oncol 2014;45:18-30.

55. Koay YC, McConnell JR, Wang Y, Kim SJ, Buckton LK, et al. Chemically accessible hsp90 inhibitor that does not induce a heat shock response. ACS Med Chem Lett 2014;5:771-6.

56. Audisio D, Methy-Gonnot D, Radanyi C, Renoir JM, Denis S, et al. Synthesis and antiproliferative activity of novobiocin analogues as potential hsp90 inhibitors. Eur J Med Chem 2014;83:498-507.

57. Radanyi C, Le Bras G, Messaoudi S, Bouclier C, Peyrat JF, et al. Synthesis and biological activity of simplified denoviose-coumarins related to novobiocin as potent inhibitors of heat-shock protein 90 (hsp90). Bioorg Med Chem Lett 2008;18:2495-8.

58. Audisio D, Messaoudi S, Cegielkowski L, Peyrat JF, Brion JD, et al. Discovery and biological activity of 6BrCaQ as an inhibitor of the Hsp90 protein folding machinery. ChemMedChem 2011;6:804-15.

59. Radanyi C, Le Bras G, Marsaud V, Peyrat JF, Messaoudi S, et al. Antiproliferative and apoptotic activities of tosylcyclonovobiocic acids as potent heat shock protein 90 inhibitors in human cancer cells. Cancer Lett 2009;274:88-94.

60. Donnelly A, Blagg BSJ. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket. Curr Med Chem 2008;15:2702-17.

61. Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, et al. KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 2009;76:1314-22.

62. Terracciano S, Russo A, Chini MG, Vaccaro MC, Potenza M, et al. Discovery of new molecular entities able to strongly interfere with Hsp90 C-terminal domain. Sci Rep 2018;8:1709.

63. Zhang FZ, Ho DHH, Wong RHF. Triptolide, a HSP90 middle domain inhibitor, induces apoptosis in triple manner. Oncotarget 2018;9:22301-15.

64. Bhatia S, Diedrich D, Frieg B, Ahlert H, Stein S, et al. Targeting HSP90 dimerization via the C terminus is effective in imatinib-resistant CML and lacks the heat shock response. Blood 2018;132:307-20.

65. Hyun SY, Le HT, Nguyen CT, Yong YS, Boo HJ, et al. Development of a novel Hsp90 inhibitor NCT-50 as a potential anticancer agent for the treatment of non-small cell lung cancer. Sci Rep 2018;8:13924.

66. Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov 2014;9:1-20.

67. Solárová Z, Mojžiš J, Solár P. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review). Int J Oncol 2015;46:907-26.

68. Ernst JT, Neubert T, Liu M, Sperry S, Zuccola H, et al. Identification of novel HSP90α/β isoform selective inhibitors using structure-based drug design. demonstration of potential utility in treating CNS disorders such as huntington’s disease. J Med Chem 2014;57:3382-400.

69. Zou M, Bhatia A, Dong H, Jayaprakash P, Guo J, et al. Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90alpha in tumour progression. Oncogene 2017;36:2160-71.

70. Yoshida S, Tsutsumi S, Muhlebach G, Sourbier C, Lee MJ, et al. Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. Proc Natl Acad Sci 2013;110:E1604-12.

71. Randow F, Seed B. Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. Nat Cell Biol 2001;3:891-6.

72. Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer 2014;14:263-76.

73. Immormino RM, Metzger LE 4th, Reardon PN, Dollins DE, Blagg BS, et al. Different poses for ligand and chaperone in inhibitor-bound Hsp90 and GRP94: implications for paralog-specific drug design. J Mol Biol 2009;388:1033-42.

74. Muth A, Crowley V, Khandelwal A, Mishra S, Zhao J, et al. Development of radamide analogs as Grp94 inhibitors. Bioorganic Med Chem 2014;22:4083-98.

75. Patel HJ, Patel PD, Ochiana SO, Yan P, Sun W, et al. Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94. J Med Chem 2015;58:3922-43.

76. Mishra SJ, Ghosh S, Stothert AR, Dickey CA, Blagg BS. Transformation of the non-selective aminocyclohexanol-based Hsp90 inhibitor into a Grp94-seletive scaffold. ACS Chem Biol 2017;12:244-53.

77. Khandelwal A, Crowley VM, Blagg BSJ. Resorcinol-Based Grp94-Selective Inhibitors. ACS Med Chem Lett 2017;8:1013-8.

78. Crowley VM, Huard DJE, Lieberman RL, Blagg BSJ. Second generation Grp94-selective inhibitors provide opportunities for the inhibition of metastatic cancer. Chem - A Eur J 2017;23:15775-82.

79. Stothert AR, Suntharalingam A, Tang X, Crowley VM, Mishra SJ, et al. Isoform-selective Hsp90 inhibition rescues model of hereditary open-angle glaucoma. Sci Rep 2017;7:17951.

80. Costantino E, Maddalena F, Calise S, Piscazzi A, Tirino V, et al. TRAP1, a novel mitochondrial chaperone responsible for multi-drug resistance and protection from apoptotis in human colorectal carcinoma cells. Cancer Lett 2009;279:39-46.

81. Palladino G, Notarangelo T, Pannone G, Piscazzi A, Lamacchia O, et al. TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells. Endocr Relat Cancer 2016;23:699-709.

82. Agorreta J, Hu J, Liu D, Delia D, Turley H, et al. Cell cycle and senescence TRAP1 regulates proliferation, mitochondrial function, and has prognostic significance in NSCLC. Mol Cancer Res 2014;12:660-9.

83. Masgras I, Sanchez-Martin C, Colombo G, Rasola A. The chaperone TRAP1 as a modulator of the mitochondrial adaptations in cancer cells. Front Oncol 2017;7:58.

84. Landriscina M, Laudiero G, Maddalena F, Amoroso MR, Piscazzi A, et al. Mitochondrial chaperone trap1 and the calcium binding protein sorcin interact and protect cells against apoptosis induced by antiblastic agents. Cancer Res 2010;70:6577-86.

85. Park HK, Jeong H, Ko E, Lee G, Lee JE, et al. Paralog specificity determines subcellular distribution, action mechanism, and anticancer activity of TRAP1 inhibitors. J Med Chem 2017;60:7569-78.

86. Plescia J, Salz W, Xia F, Pennati M, Zaffaroni N, et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005;7:457-68.

87. Kang BH, Plescia J, Song HY, Meli M, Colombo G, et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 2009;119:454-64.

88. Zielonka J, Joseph J, Sikora A, Hardy M, Ouari O, et al. Mitochondria-targeted triphenylphosphonium-based compounds: syntheses, mechanisms of action, and therapeutic and diagnostic applications. Chem Rev 2017;117:10043-120.

89. Rondanin R, Lettini G, Oliva P, Baruchello R, Costantini C, et al. New TRAP1 and Hsp90 chaperone inhibitors with cationic components: preliminary studies on mitochondrial targeting. Bioorganic Med Chem Lett 2018;28:2289-93.

90. Yoo SH, Kim HY, Rho JH, Jeong SY, Yun J, et al. Targeted inhibition of mitochondrial Hsp90 induces mitochondrial elongation in Hep3B hepatocellular carcinoma cells undergoing apoptosis by increasing the ROS level. Int J Oncol 2015;47:1783-92.

91. Yan C, Oh JS, Yoo SH, Lee JS, Yoon YG, et al. The targeted inhibition of mitochondrial Hsp90 overcomes the apoptosis resistance conferred by Bcl-2 in Hep3B cells via necroptosis. Toxicol Appl Pharmacol 2013;266:9-18.

92. Ishida CT, Canoll P, Bruce JN, Roth KA, Siegelin MD, et al. Inhibition of mitochondrial matrix chaperones and antiapoptotic Bcl-2 family proteins empower antitumor therapeutic responses. Cancer Res 2017;77:3513-26.

93. Kang BH, Siegelin MD, Plescia J, Raskett CM, Garlick DS, et al. Preclinical characterization of mitochondria-targeted small molecule hsp90 inhibitors, gamitrinibs, in advanced prostate cancer. Clin Cancer Res 2010;16:4779-88.

94. Hou XS, Wang HS, Mugaka BP, Yang GJ, Ding Y. Mitochondria: promising organelle targets for cancer diagnosis and treatment. Biomater Sci 2018;6:2786-97.

95. Amoroso MR, Matassa DS, Agliarulo I, Avolio R, Maddalena F, et al. Stress-adaptive response in ovarian cancer drug resistance: role of TRAP1 in oxidative metabolism-driven inflammation. Adv Protein Chem Struct Biol 2017;108:163-98.

96. Sciacovelli M, Guzzo G, Morello V, Frezza C, Zheng L, et al. The mitochondrial chaperone TRAP1 promotes neoplastic growth by inhibiting succinate dehydrogenase. Cell Metab 2013;17:988-99.

97. Matassa DS, Agliarulo I, Avolio R, Landriscina M, Esposito F. Trap1 regulation of cancer metabolism: dual role as oncogene or tumor suppressor. Genes (Basel) 2018;9:195.

98. Maddalena F, Sisinni L, Lettini G, Condelli V, Matassa DS, et al. Resistance to paclitxel in breast carcinoma cells requires a quality control of mitochondrial antiapoptotic proteins by TRAP1. Mol Oncol 2013;7:895-906.

99. Calero R, Morchon E, Martinez-Argudo I, Serrano R. Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma. Cancer Lett 2017;406:1-11.

100. Wang H, Sun M, Guo J, Ma L, Jiang H, et al. 3-O-(Z)-coumaroyloleanolic acid overcomes Cks1b-induced chemoresistance in lung cancer by inhibiting Hsp90 and MEK pathways. Biochem Pharmacol 2017;135:35-49.

101. McLaughlin M, Barker HE, Khan AA, Pedersen M, Dillon M, et al. HSP90 inhibition sensitizes head and neck cancer to platin-based chemoradiotherapy by modulation of the DNA damage response resulting in chromosomal fragmentation. BMC Cancer 2017;17:86.

102. Jacobson C, Kopp N, Layer JV, Redd RA, Tschuri S, et al. HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. Blood 2016;128:2517-26.

103. Park KS, Yang H, Choi J, Seo S, Kim D, et al. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer. Cancer Lett 2017;406:47-53.

104. Park KS, Oh B, Lee MH, Nam KY, Jin HR, et al. The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib. Cancer Lett 2016;372:75-81.

105. Bai J, Zhou G, Qiu Y, Hu Y, Liu J, et al. HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells. Cancer Sci 2017;108:1177-84.

106. Geng K, Liu H, Song Z, Zhang C, Zhang M, et al. Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. Eur J Med Chem 2018;152:76-86.

107. Jiang J, Lu Y, Li Z, Li L, Niu D, et al. Ganetespib overcomes resistance to PARP inhibitors in breast cancer by targeting core proteins in the DNA repair machinery. Invest New Drugs 2017;35:251-9.

108. Huang L, Wei G, Sun X, Jiang Y, Huang Z, et al. A tumor-targeted Ganetespib-zinc phthalocyanine conjugate for synergistic chemo-photodynamic therapy. Eur J Med Chem 2018;151:294-303.

109. Jhaveri K, Wang R, Teplinsky E, Chandarlapaty S, Solit D, et al. A phase I trial of ganetespib in combination with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer. Breast Cancer Res 2017;19:89.

110. Cavenagh J, Oakervee H, Baetiong-Caguioa P, Davies F, Gharibo M, et al. A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. Br J Cancer 2017;117:1295-302.

111. Sauvage F, Messaoudi S, Fattal E, Barratt G, Vergnaud-Gauduchon J. Heat shock proteins and cancer: how can nanomedicine be harnessed? J Control Release 2017;248:133-43.

112. Le B, Powers GL, Tam YT, Schumacher N, Malinowski RL, et al. Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/ mTOR pathway in prostate cancer. PLoS One 2017;12:e0174658.

113. Shin DH, Kwon GS. Pre-clinical evaluation of a themosensitive gel containing epothilone B and mTOR/Hsp90 targeted agents in an ovarian tumor model. J Control Release 2017;268:176-83.

114. Peng CL, Shieh MJ, Lee PC, Liu HJ, Chen YI, et al. A novel temperature-responsive micelle for enhancing combination therapy. Int J Nanomedicine 2016;11:3357-69.

115. Long Q, Lin TY, Huang Y, Li X, Ma AH, et al. Image-guided photo-therapeutic nanoporphyrin synergized HSP90 inhibitor in patient-derived xenograft bladder cancer model. Nanomedicine 2018;14:789-99.

116. Sauvage F, Fattal E, Al-Shaer W, Denis S, Brotin E, et al. Antitumor activity of nanoliposomes encapsulating the novobiocin analog 6BrCaQ in a triple-negative breast cancer model in mice. Cancer Lett 2018;432:103-11.

117. Sauvage F, Franzè S, Bruneau A, Alami M, Denis S, et al. Formulation and in vitro efficacy of liposomes containing the Hsp90 inhibitor 6BrCaQ in prostate cancer cells. Int J Pharm 2016;499:101-9.

118. Rahimi MN, Foster H, Farazi S, Chapman R, McAlpine SR. Polymer mediated transport of the Hsp90 inhibitor LB76, a polar cyclic peptide, produces an Hsp90 cellular phenotype. Chem Commun (Camb) 2019;55:4515-8.

119. Mondal SK, Jinka S, Pal K, Nelli S, Dutta SK, et al. Glucocorticoid receptor-targeted liposomal codelivery of lipophilic drug and anti-Hsp90 gene: strategy to induce drug-sensitivity, EMT-reversal, and reduced malignancy in aggressive tumors. Mol Pharm 2016;13:2507-23.

120. Pore SK, Choudhary A, Rathore B, Ganguly A, Sujitha P, et al. Hsp90-targeted miRNA-liposomal formulation for systemic antitumor effect. Biomaterials 2013;34:6804-17.

121. Mitra K, Samsó M, Lyons CE, Hartman MCT. Hyaluronic acid grafted nanoparticles of a platinum(ii)-silicon(iv) phthalocyanine conjugate for tumor and mitochondria-targeted photodynamic therapy in red light. J Mater Chem B 2018;6:7373-7.

122. Wang K, Qi M, Guo C, Yu Y, Wang B, et al. Novel dual mitochondrial and CD44 receptor targeting nanoparticles for redox stimuli-triggered release. Nanoscale Res Lett 2018;13:32.

123. Thomas AP, Palanikumar L, Jeena MT, Kim K, Ryu JH. Cancer-mitochondria-targeted photodynamic therapy with supramolecular assembly of HA and a water soluble NIR cyanine dye. Chem Sci 2017;8:8351-6.

124. Wei G, Wang Y, Huang X, Yang G, Zhao J, et al. Induction of mitochondrial apoptosis for cancer therapy: Via dual-targeted cascade-responsive multifunctional micelles. J Mater Chem B 2018;6:8137-47.

Cancer Drug Resistance
ISSN 2578-532X (Online)
Follow Us


All published articles will preserved here permanently:


All published articles will preserved here permanently: